Charles W. Allen

Charles W. Allen, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in BTCS Inc. and 60 Degrees Pharmaceuticals, Inc. We count 81 filings; the first trade dates from 3 September 2014 and the latest from 15 June 2026.

In open-market terms, that means 17 purchases worth €316k on one side and 13 sales worth €1.5M on the other. No amount is published for 2 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 18 share grants and 6 option exercises. So far in 2026, the count stands at no purchases and 5 sales.

In size, the median ticket on the buying side is €4,725. Across 6 purchases, this insider has always bought alone, with no colleague buying within 30 days. Looking at 10 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -40.3%. These figures describe past trades and do not predict future prices.

The latest filing, published on 16 June 2026, reports an open-market sale of €86k in BTCS Inc. The most recent open-market purchase was published on 19 November 2025, 339 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.